Aleksic S, Szabo Z, Scheffel U, Ravert H T, Mathews W B, Kerenyi L, Rauseo P A, Gibson R E, Burns H D, Dannals R F
Division of Nuclear Medicine, Department of Radiology, The Johns Hopkins Medical Institutions, Baltimore, Maryland, USA.
J Nucl Med. 2001 Aug;42(8):1274-80.
Endothelin (ET) is a potent mammalian vasoconstrictive peptide and a pressor agent. Its 3 isoforms, ET-1, ET-2, and ET-3, mediate several physiologic actions in several organ systems, binding to 2 major receptor subtypes: ET(A) and ET(B). This study was undertaken to evaluate [(11)C]L-753,037 [(+)-(5S,6R,7R)-2-butyl-7-[2-((2S)-2-carboxy-propyl)-4-methoxyphenyl]-5-(3,4-methylenedioxyphenyl)cyclopenteno [1,2-beta]pyridine-6-carboxylate), a new mixed ET receptor A and B antagonist, as a tracer for in vivo labeling of ET receptors in mice and a dog.
[(11)C]L-753,037 was synthesized, purified, and formulated from a normethyl precursor, L-843,974, and [(11)C]H(3)I. The tracer was studied for its in vivo kinetics, biodistribution, and ET receptor binding characteristics in mice. In the dog, PET imaging was performed to evaluate binding of [(11)C]L-753,037 to ET receptors in the heart. Specificity of binding was studied in the heart with the selective ET(A) antagonist L-753,164.
Kinetic studies in mice showed highest tracer uptake at 5 min after injection in liver (25.0 percentage injected dose per gram [%ID/g]), kidneys (18.7 %ID/g), lungs (15.2 %ID/g), and heart (5.6 %ID/g). Initial high uptake in liver, lungs, and kidneys was followed by rapid washout during the next 10 min and a very slow clearance during the time of observation (2 h after injection). By contrast, the radioactivity in the heart remained constant over 2 h. Administration of both ET(A) (L-753,164) and mixed ET(A)/ET(B) (L-753,137) receptor antagonists resulted in dose-dependent inhibition of [(11)C]L-753,037 binding in mouse heart, lungs, and kidneys but not in the liver. Radioactivity in the brain was very low, indicating that the tracer does not cross the blood-brain barrier. In the dog, a dynamic PET study of the heart showed high tracer accumulation at 55-95 min after injection. Injection of L-753,164 at 30 min before [(11)C]L-753,037 administration led to a significant reduction in tracer binding. [(11)C]methyl triphenyl phosphonium was used as a tracer for reference images of the dog heart muscle.
The results suggest that [(11)C]L-753,037 binds to ET receptors in vivo and is, therefore, a promising candidate for investigation of these receptors and their occupancy by ET receptor antagonists using PET.
内皮素(ET)是一种强效的哺乳动物血管收缩肽和升压剂。其三种异构体,即ET-1、ET-2和ET-3,在多个器官系统中介导多种生理作用,可与两种主要受体亚型ET(A)和ET(B)结合。本研究旨在评估[(11)C]L-753,037[(+)-(5S,6R,7R)-2-丁基-7-[2-((2S)-2-羧基丙基)-4-甲氧基苯基]-5-(3,4-亚甲基二氧基苯基)环戊烯并[1,2-β]吡啶-6-羧酸酯],一种新型的ET受体A和B混合型拮抗剂,作为小鼠和犬体内ET受体放射性标记的示踪剂。
[(11)C]L-753,037由正常甲基前体L-843,974和[(11)C]H3I合成、纯化并配制而成。对该示踪剂在小鼠体内的动力学、生物分布和ET受体结合特性进行了研究。在犬体内,进行正电子发射断层显像(PET)以评估[(11)C]L-753,037与心脏ET受体的结合情况。使用选择性ET(A)拮抗剂L-753,164对心脏结合的特异性进行了研究。
小鼠的动力学研究显示,注射后5分钟时,示踪剂在肝脏(25.0%注射剂量/克[%ID/g])、肾脏(18.7%ID/g)、肺(15.2%ID/g)和心脏(5.6%ID/g)中的摄取量最高。肝脏、肺和肾脏最初的高摄取量之后,在接下来的10分钟内迅速清除,在观察期(注射后2小时)内清除非常缓慢。相比之下,心脏中的放射性在2小时内保持恒定。给予ET(A)(L-753,164)和ET(A)/ET(B)混合型(L-753,137)受体拮抗剂均导致[(11)C]L-753,037在小鼠心脏、肺和肾脏中的结合呈剂量依赖性抑制,但在肝脏中无此现象。脑中的放射性非常低,表明该示踪剂不能穿过血脑屏障。在犬体内,心脏的动态PET研究显示注射后55 - 95分钟时示踪剂高度蓄积。在给予[(11)C]L-753,037前30分钟注射L-753,164导致示踪剂结合显著减少。[(11)C]甲基三苯基鏻用作犬心肌参考图像的示踪剂。
结果表明[(11)C]L-753,037在体内与ET受体结合,因此,它是使用PET研究这些受体及其被ET受体拮抗剂占据情况的一个有前景的候选物。